A Predictive Level of C-peptide for Glutamic Acid Decarboxylase Antibody Positivity in Autoimmune Diabetes

Abstract

Objective: Diabetes mellitus (DM) is one of the most prevalent chronic diseases and is considered a universal health issue. This study aimed to establish a C-peptide cut-off level to predict glutamic acid decarboxylase antibody 65 (GADA) positivity in autoimmune diabetes. Methods: Designed as a retrospective methodological study, the study reviewed diabetic patients aged over 16 years who presented to adult internal medicine outpatient clinics between 2008 and 2022. The data were collected retrospectively from the hospital records. Patients were categorized into two groups according to GADA positivity, and their sensitivity and specificity were calculated for fasting C-peptide levels. Results: GADA positivity was observed in 96 of a total of 343 patients. The group with antibody positivity was younger (p < .001), had lower C-peptide levels (p < .001) and higher HbA1c levels (p = .03). Thyroid antibody positivity was more common in this group (p = .009). Sensitivity was 80.2% and specificity was 72.5% for the optimal C-peptide level cut-off point of ≤ 1.35 ng/mL, which predicted GADA positivity. Conclusion: GADA positivity was highly prevalent at a fasting C-peptide level cut-off point of ≤1.35 ng/mL. Hence, in clinical practice, GADA could be routinely examined in patients with a value below this level for accurate diagnosis and early initiation of treatment in autoimmune diabetes.

Keywords

• Glutamic Acid Decarboxylase Antibody 65
• C-peptide
• Diabetes Mellitus; Autoimmune Diabetes

References

1. 1.ElSayed NA, Aleppo G, Aroda VR, et al. 2.Classification and Diagnosis of Diabetes: Standardsof Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1): 19-40.
2. 2.Bingley PJ. Clinical applications of diabetesantibody testing. J Clin Endocrinol Metab. 2010;95(1): 25-33.
3. 3.Herawati E, Susanto A, Sihombing CN.Autoantibodies in Diabetes Mellitus. Mol CellBiomed Sci. 2017; 1(2): 58-64.
4. 4.Desai M, Clark A. Autoimmune diabetes in adults:lessons from the UKPDS. Diabet Med. 2008;25(Suppl 2): 30-4.
5. 5.Fagbemi KA, Azonbakin S, Adjagba M, et al. GAD65antibody prevalence and association with c-peptide,HLA class II alleles in Beninese patients with type 1diabetes. Int J Res Med Sci. 2017; 5(8): 3406-12.
6. 6.Leighton E, Sainsbury CA, Jones GC. A PracticalReview of C-Peptide Testing in Diabetes. DiabetesTher. 2017; 8(3): 475-87.
7. 7.Patel P, Macerollo A. Diabetes mellitus: diagnosisand screening. Am Fam Physician. 2010; 81(7): 863-70.
8. 8.Handelsman Y, Bloomgarden ZT, Grunberger G, etal. American Association of Clinical Endocrinologistsand American College of Endocrinology--ClinicalPractice Guidelines for Developing a DiabetesMellitus Comprehensive Care Plan--2015--Executive Summary. Endocr Pract. 2015; 21(4):413-37.

9. 9.Koopman ADM, Beulens JW, Voerman E, et al. Theassociation between GAD65 antibody levels andincident Type 2 Diabetes Mellitus in an adultpopulation: A meta-analysis. Metabolism. 2019; 95:1-7.
10. 10.Brahmkshatriya PP, Mehta AA, Saboo BD, GoyalRK. Characteristics and Prevalence of LatentAutoimmune Diabetes in Adults (LADA). ISRNPharmacol. 2012; 2012: 580202.
11. 11.Zhou Z, Xiang Y, Ji L, et al. Frequency,immunogenetics, and clinical characteristics oflatent autoimmune diabetes in China (LADA Chinastudy): a nationwide, multicenter, clinic-basedcross-sectional study. Diabetes. 2013; 62(2): 543-50.
12. 12.Mollo A, Hernandez M, Marsal JR, et al. Latentautoimmune diabetes in adults is perched betweentype 1 and type 2: evidence from adults in one regionof Spain. Diabetes Metab Res Rev. 2013; 29(6): 446-51.
13. 13.Arikan E, Sabuncu T, Ozer EM, Hatemi H. Theclinical characteristics of latent autoimmunediabetes in adults and its relation with chroniccomplications in metabolically poor controlledTurkish patients with Type 2 diabetes mellitus. J Diabetes Complications. 2005; 19(5): 254-8.
14. 14.Fan B, Lim CKP, Poon EWM, et al. DifferentialAssociations of GAD Antibodies (GADA) and C-Peptide With Insulin Initiation, Glycemic Responses,and Severe Hypoglycemia in Patients DiagnosedWith Type 2 Diabetes. Diabetes Care. 2023; 46(6):1282-91.
15. 15.Maddaloni E, Bolli GB, Frier BM, et al. C-peptidedetermination in the diagnosis of type of diabetesand its management: A clinical perspective. DiabetesObes Metab. 2022; 24(10): 1912-26.
16. 16.Li X, Huang G, Lin J, Yang L, Zhou Z. Variation of Cpeptide decay rate in diabetic patients with positiveglutamic acid decarboxylase antibody: betterdiscrimination with initial fasting C peptide. BMCEndocr Disord. 2013; 13: 10.
17. 17.Becht FS, Walther K, Martin E, Nauck MA. FastingC-peptide and Related Parameters CharacterizingInsulin Secretory Capacity for Correctly ClassifyingDiabetes Type and for Predicting InsulinRequirement in Patients with Type 2 Diabetes. ExpClin Endocrinol Diabetes. 2016; 124(3): 148-56.
18. 18.Tuomi T, Carlsson A, Li H, et al. Clinical andgenetic characteristics of type 2 diabetes with andwithout GAD antibodies. Diabetes. 1999; 48(1): 150-7.
19. 19.Hwangbo Y, Kim JT, Kim EK, et al. Prevalence andclinical characteristics of recently diagnosed type 2diabetes patients with positive anti-glutamic Aciddecarboxylase antibody. Diabetes Metab J. 2012;36(2): 136-43.
20. 20.Selman NA, Albayati AHA, Alsaffar Y. Role ofantiGAD65 Ab., C-peptide level and clinicalcharacteristics in classification of newly diagnoseddiabetes in patients aged 20-40 years. Annals ofTropical Medicine and Public Health. 2020; 23(4):133-8.
21. 21.Das S, Routray D, Behera M, Tripathy S. Role of C-Peptide in Relation to Levels of Anti-GAD and IsletCell Antibodies in Characterizing Types of Diabetesin the Young, in Eastern India. Journal of DiabetesMellitus. 2021; 12: 1-11.
22. 22.Foteinopoulou E, Clarke CAL, Pattenden RJ, et al.Impact of routine clinic measurement of serum C- peptide in people with a clinician-diagnosis of type 1 diabetes. Diabet Med. 2021; 38(7): e14449.
23. 23.Naik RG, Palmer JP. Latent autoimmune diabetesin adults (LADA). Rev Endocr Metab Disord. 2003;4(3): 233-41.
24. 24.Kim CS, Nam JH, Nam JS, et al. Clinical andbiochemical characteristics of nonobese type 2diabetic patients with glutamic acid decarboxylaseantibody in Korea. Metabolism. 2006; 55(8): 1107-12.
25. 25.Wan Nazaimoon WM, Faridah I, Singaraveloo M,et al. Prevalence of glutamic acid decarboxylaseantibodies amongst young Malaysian diabetics.Diabetes Res Clin Pract. 1999; 43(1): 59-66.
26. 26.Tuomi T, Santoro N, Caprio S, et al. The manyfaces of diabetes: a disease with increasingheterogeneity. Lancet. 2014; 383(9922): 1084-94.
27. 27.Törn C, Landin-Olsson M, Lernmark A, et al.Prognostic factors for the course of beta cell functionin autoimmune diabetes. J Clin Endocrinol Metab.2000; 85(12): 4619-23.
28. 28.Cho MJ, Kim MS, Kim CJ, et al. Fasting serum C-peptide is useful for initial classification of diabetesmellitus in children and adolescents. Ann Pediatr Endocrinol Metab. 2014; 19(2): 80-5.
29. 29.Holt RIG, DeVries JH, Hess-Fischl A, et al. TheManagement of Type 1 Diabetes in Adults. AConsensus Report by the American DiabetesAssociation (ADA) and the European Association forthe Study of Diabetes (EASD). Diabetes Care. 2021;44(11): 2589-625.
30. 30.Rahmati M, Keshvari M, Mirnasuri S, et al. Theglobal impact of COVID-19 pandemic on theincidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic review and meta-analysis. J Med Virol. 2022; 94(11): 5112-27.
31. 31.Iughetti L, Trevisani V, Cattini U, et al. COVID-19and Type 1 Diabetes: Concerns and Challenges. ActaBiomed. 2020; 91(3): e2020033.
32. 32.Boddu SK, Aurangabadkar G, Kuchay MS. Newonset diabetes, type 1 diabetes and COVID-19.Diabetes Metab Syndr. 2020; 14(6): 2211-7.
33. 33.Bárová H, Perusicová J, Hill M, et al. Anti-GAD-positive patients with type 1 diabetes mellitus havehigher prevalence of autoimmune thyroiditis thananti-GAD-negative patients with type 1 and type 2diabetes mellitus. Physiol Res. 2004; 53(3): 279-86.